focus-germany's merck seeks partners for cancer and immune system drugs

frankfurt
reuters
merck
kgaa
seek
development
partners
experimental
treatments
including
tepotinib
german
company
looks
licensing
deals
help
fund
clinical
trials
according
head
drug
r
d
merck
has
promising
drug
pipeline
first
time
several
years
it
is
looking
take
collaborative
approach
expected
decline
operating
profit
year
forces
it
find
new
ways
finance
pharmaceutical
development
luciano
rossetti
drug
research
development
chief
told
reuters
company
was
engaged
very
intense
ongoing
conversations
deals
help
fund
trials
drugs
pipeline
he
said
merck
was
looking
strike
agreements
treatments
including
oral
lung
cancer
drug
tepotinib
as
well
bifunctional
fusion
protein
earlier
stage
development
which
aims
assist
immune
system
fighting
cancer
cells
merck
did
not
disclose
names
potential
partners
rossetti
said
company
was
preparing
present
initial
phase
trial
data
tepotinib
american
society
clinical
oncology
asco
chicago
june
which
he
expected
show
drug
blocks
genetic
mutation
that
drives
tumor
growth
certain
lung
cancer
cases
we
expect
approach
is
have
high
response
rate
patient
population
said
rossetti
adding
asco
had
final
word
findings
be
presented
conference
bernstein
analysts
said
march
note
tepotinib
was
one
watch
merck
s
early
pipeline
drugs
predicted
sales
million
million
licence
partnership
agreements
which
typically
see
drugmaker
share
cost
trials
pharma
biotech
firm
return
share
future
sales
offer
merck
way
drive
promising
drug
pipeline
as
many
disease
types
possible
however
such
deals
are
they
curb
risk
they
also
curb
earnings
merck
diversified
company
that
also
has
chemicals
lab
equipment
divisions
does
not
have
financial
firepower
pharmaceuticals
sector
s
biggest
players
including
roche
pfizer
novartis
sanofi
prevent
it
challenging
larger
rivals
acquiring
assets
consolidating
global
market
analysts
say
pharma
majors
often
buy
certain
rights
experimental
drugs
rivals
smaller
biotech
firms
bolster
pipeline
selling
rights
outlicensing
is
also
common
is
mainly
driven
desire
win
partners
unfamiliar
markets
rather
financial
constraints
merck
s
bifunctional
fusion
protein
which
combines
approved
cancer
drug
bavencio
s
immunotherapy
mechanism
second
immune
trigger
is
phase
trials
drugs
typically
go
three
phases
testing
market
launch
cancer
be
cut
short
two
when
regulators
see
sufficient
promise
merck
which
started
years
ago
apothecary
shop
german
city
darmstadt
sells
products
ranging
pearlescent
pigments
dimmable
window
panes
healthcare
pharmaceuticals
allergy
treatments
consumer
health
accounted
percent
billion
euros
sales
last
year
merck
struck
deal
week
sell
consumer
health
unit
procter
gamble
co
billion
euros
company
said
not
affect
plans
seek
partners
help
develop
pharma
pipeline
group
is
bind
just
it
turned
drug
pipeline
promising
candidates
arthritis
cancer
finances
have
been
squeezed
chinese
competition
biggest
cash
generator
liquid
crystals
tv
screens
means
it
is
lacking
money
take
drug
candidates
forward
own
steam
shares
have
fallen
percent
past
year
compared
percent
decline
european
pharma
index
percent
gain
european
chemicals
index
considering
merck
had
next
pipeline
five
years
they
ve
built
something
quite
solid
said
markus
manns
portfolio
manager
union
investment
which
holds
shares
german
company
investor
i
wouldn
t
want
take
earnings
hit
merck
were
decide
go
it
alone
pharmaceuticals
he
added
many
pharma
biotech
players
were
eager
grab
slice
other
companies
promising
new
treatments
putting
merck
very
comfortable
position
merck
when
it
flagged
collaborative
approach
drug
development
last
month
had
highlighted
evobrutinib
btk
inhibitor
designed
block
white
blood
cells
launching
immune
response
healthy
cells
it
is
second
phase
testing
drug
s
potentially
broad
use
autoimmune
market
including
rheumatoid
arthritis
multiple
sclerosis
lupus
attract
prospective
partners
such
abbvie
roche
said
manns
bernstein
has
identified
merck
s
stock
bargain
due
low
market
expectations
merck
kgaa
s
pipeline
is
often
overlooked
investors
rightly
so
given
lack
visibility
poor
track
record
said
analyst
wimal
kapadia
given
most
investors
expect
failure
is
euros
editing
pravin
char
